| UniProt ID | VLDLR_HUMAN | |
|---|---|---|
| UniProt AC | P98155 | |
| Protein Name | Very low-density lipoprotein receptor | |
| Gene Name | VLDLR | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 873 | |
| Subcellular Localization |
Membrane Single-pass type I membrane protein. Membrane, clathrin-coated pit Single-pass type I membrane protein. |
|
| Protein Description | Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation (By similarity).. | |
| Protein Sequence | MGTSALWALWLLLALCWAPRESGATGTGRKAKCEPSQFQCTNGRCITLLWKCDGDEDCVDGSDEKNCVKKTCAESDFVCNNGQCVPSRWKCDGDPDCEDGSDESPEQCHMRTCRIHEISCGAHSTQCIPVSWRCDGENDCDSGEDEENCGNITCSPDEFTCSSGRCISRNFVCNGQDDCSDGSDELDCAPPTCGAHEFQCSTSSCIPISWVCDDDADCSDQSDESLEQCGRQPVIHTKCPASEIQCGSGECIHKKWRCDGDPDCKDGSDEVNCPSRTCRPDQFECEDGSCIHGSRQCNGIRDCVDGSDEVNCKNVNQCLGPGKFKCRSGECIDISKVCNQEQDCRDWSDEPLKECHINECLVNNGGCSHICKDLVIGYECDCAAGFELIDRKTCGDIDECQNPGICSQICINLKGGYKCECSRGYQMDLATGVCKAVGKEPSLIFTNRRDIRKIGLERKEYIQLVEQLRNTVALDADIAAQKLFWADLSQKAIFSASIDDKVGRHVKMIDNVYNPAAIAVDWVYKTIYWTDAASKTISVATLDGTKRKFLFNSDLREPASIAVDPLSGFVYWSDWGEPAKIEKAGMNGFDRRPLVTADIQWPNGITLDLIKSRLYWLDSKLHMLSSVDLNGQDRRIVLKSLEFLAHPLALTIFEDRVYWIDGENEAVYGANKFTGSELATLVNNLNDAQDIIVYHELVQPSGKNWCEEDMENGGCEYLCLPAPQINDHSPKYTCSCPSGYNVEENGRDCQSTATTVTYSETKDTNTTEISATSGLVPGGINVTTAVSEVSVPPKGTSAAWAILPLLLLVMAAVGGYLMWRNWQHKNMKSMNFDNPVYLKTTEEDLSIDIGRHSASVGHTYPAISVVSTDDDLA | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 71 | O-linked_Glycosylation | EKNCVKKTCAESDFV CCCEEEHHHHCCCEE | 15.95 | 55825159 | |
| 151 | N-linked_Glycosylation | EDEENCGNITCSPDE CCCCCCCCCEECCCC | 28.70 | UniProtKB CARBOHYD | |
| 153 | O-linked_Glycosylation | EENCGNITCSPDEFT CCCCCCCEECCCCEE | 15.78 | OGP | |
| 192 | O-linked_Glycosylation | ELDCAPPTCGAHEFQ CCCCCCCCCCCCEEE | 23.63 | OGP | |
| 277 | O-linked_Glycosylation | EVNCPSRTCRPDQFE CCCCCCCCCCCCCEE | 19.73 | 55823601 | |
| 524 | Phosphorylation | AIAVDWVYKTIYWTD HHHHHEEHHHHCCCC | 9.73 | - | |
| 759 | Phosphorylation | TATTVTYSETKDTNT CCEEEEEECCCCCCC | 29.44 | - | |
| 765 | N-linked_Glycosylation | YSETKDTNTTEISAT EECCCCCCCCEEEEC | 55.95 | UniProtKB CARBOHYD | |
| 781 | N-linked_Glycosylation | GLVPGGINVTTAVSE CCCCCCEEEEEEEEE | 28.49 | UniProtKB CARBOHYD | |
| 800 (in isoform 2) | Ubiquitination | - | 5.42 | 21890473 | |
| 828 (in isoform 1) | Ubiquitination | - | 56.82 | 21890473 | |
| 828 | Ubiquitination | NWQHKNMKSMNFDNP CCCCCCCCCCCCCCC | 56.82 | 21890473 | |
| 837 | Phosphorylation | MNFDNPVYLKTTEED CCCCCCEEEEECCCC | 12.07 | 21945579 | |
| 839 | Ubiquitination | FDNPVYLKTTEEDLS CCCCEEEEECCCCEE | 35.40 | 20427281 | |
| 846 | Phosphorylation | KTTEEDLSIDIGRHS EECCCCEEEECCCCC | 30.45 | 30576142 | |
| 853 | Phosphorylation | SIDIGRHSASVGHTY EEECCCCCCCCCCCC | 22.37 | 28450419 | |
| 855 | Phosphorylation | DIGRHSASVGHTYPA ECCCCCCCCCCCCCC | 31.48 | 28450419 | |
| 859 | Phosphorylation | HSASVGHTYPAISVV CCCCCCCCCCCEEEE | 25.85 | 28450419 | |
| 860 | Phosphorylation | SASVGHTYPAISVVS CCCCCCCCCCEEEEE | 5.74 | 25884760 | |
| 864 | Phosphorylation | GHTYPAISVVSTDDD CCCCCCEEEEECCCC | 20.69 | 26437602 | |
| 867 | Phosphorylation | YPAISVVSTDDDLA- CCCEEEEECCCCCC- | 24.78 | 22617229 | |
| 868 | Phosphorylation | PAISVVSTDDDLA-- CCEEEEECCCCCC-- | 31.66 | 30576142 |
| Modified Location | Modified Residue | Modification | Function | Reference |
|---|---|---|---|---|
| 839 | K | ubiquitylation |
| 20427281 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of VLDLR_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| DAB1_HUMAN | DAB1 | physical | 10827173 | |
| SNX17_HUMAN | SNX17 | physical | 12169628 | |
| MYLIP_HUMAN | MYLIP | physical | 21734303 | |
| RELN_HUMAN | RELN | physical | 10571240 | |
| CLUS_MOUSE | Clu | physical | 12824284 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| H01204 | Cerebellar ataxia, mental retardation (MR), and dysequilibrium syndrome (CAMRQ) | |||||
| OMIM Disease | ||||||
| 224050 | Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 (CAMRQ1) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Ubiquitylation | |
| Reference | PubMed |
| "The E3 ubiquitin ligase IDOL induces the degradation of the lowdensity lipoprotein receptor family members VLDLR and ApoER2."; Hong C., Duit S., Jalonen P., Out R., Scheer L., Sorrentino V.,Boyadjian R., Rodenburg K.W., Foley E., Korhonen L., Lindholm D.,Nimpf J., van Berkel T.J., Tontonoz P., Zelcer N.; J. Biol. Chem. 285:19720-19726(2010). Cited for: UBIQUITINATION AT LYS-839 BY MYLIP, GLYCOSYLATION, AND MUTAGENESIS OFLYS-825; LYS-828 AND LYS-839. | |